JP2022526621A5 - - Google Patents
Info
- Publication number
- JP2022526621A5 JP2022526621A5 JP2021559414A JP2021559414A JP2022526621A5 JP 2022526621 A5 JP2022526621 A5 JP 2022526621A5 JP 2021559414 A JP2021559414 A JP 2021559414A JP 2021559414 A JP2021559414 A JP 2021559414A JP 2022526621 A5 JP2022526621 A5 JP 2022526621A5
- Authority
- JP
- Japan
- Prior art keywords
- mammal
- bay
- sgc
- methyl
- iwp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025123759A JP2025172729A (ja) | 2019-04-10 | 2025-07-24 | 心血管機能障害の性別依存性処置のための方法及び材料 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832139P | 2019-04-10 | 2019-04-10 | |
| US62/832,139 | 2019-04-10 | ||
| PCT/US2020/027777 WO2020210707A1 (en) | 2019-04-10 | 2020-04-10 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025123759A Division JP2025172729A (ja) | 2019-04-10 | 2025-07-24 | 心血管機能障害の性別依存性処置のための方法及び材料 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526621A JP2022526621A (ja) | 2022-05-25 |
| JP2022526621A5 true JP2022526621A5 (https=) | 2023-06-05 |
Family
ID=72752121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559414A Withdrawn JP2022526621A (ja) | 2019-04-10 | 2020-04-10 | 心血管機能障害の性別依存性処置のための方法及び材料 |
| JP2025123759A Pending JP2025172729A (ja) | 2019-04-10 | 2025-07-24 | 心血管機能障害の性別依存性処置のための方法及び材料 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025123759A Pending JP2025172729A (ja) | 2019-04-10 | 2025-07-24 | 心血管機能障害の性別依存性処置のための方法及び材料 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12465605B2 (https=) |
| EP (1) | EP3952992A4 (https=) |
| JP (2) | JP2022526621A (https=) |
| KR (1) | KR20210150495A (https=) |
| CN (1) | CN114144229A (https=) |
| AU (2) | AU2020273183A1 (https=) |
| CA (1) | CA3136550A1 (https=) |
| IL (1) | IL287073A (https=) |
| MX (2) | MX2021012409A (https=) |
| SG (1) | SG11202110533RA (https=) |
| WO (1) | WO2020210707A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117357506A (zh) * | 2023-09-11 | 2024-01-09 | 重庆医科大学国际体外诊断研究院 | 丹酚酸a在治疗钙化性主动脉瓣膜疾病中的用途 |
| CN117969836B (zh) * | 2024-03-29 | 2024-06-04 | 北京市心肺血管疾病研究所 | 基于血浆炎症蛋白构建主动脉瓣钙化狭窄诊断模型及应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR22934E (fr) | 1919-07-19 | 1921-09-06 | Albert Jean Baptiste Hanotelle | Sifflet électro-automoteur perfectionné pour répétition des signaux sur la locomotive |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| WO1998038168A1 (en) | 1997-02-27 | 1998-09-03 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
| US6723719B1 (en) | 1997-04-25 | 2004-04-20 | Pfizer Inc | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction |
| AU755361B2 (en) | 1998-02-19 | 2002-12-12 | Eisai R&D Management Co., Ltd. | Phthalazine derivatives and remedies for erectile dysfunction |
| CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| US6774128B2 (en) | 2000-04-19 | 2004-08-10 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
| JP2004501124A (ja) | 2000-06-07 | 2004-01-15 | リリー アイコス リミテッド ライアビリティ カンパニー | 化合物 |
| US6911542B2 (en) | 2000-06-23 | 2005-06-28 | Lilly Icos Llc. | Pyrazino[1′,2′:1,6]pyrido[3,4b]indole derivatives |
| MXPA02012470A (es) | 2000-06-23 | 2004-01-26 | Lilly Icos Llc | Inhibidores de fosfodiesterasa especificos para gmp ciclico. |
| MXPA02012659A (es) | 2000-06-26 | 2003-09-22 | Lilly Icos Llc | Derivados de pirazindiona condensados. |
| DE60121461T2 (de) | 2000-10-03 | 2007-02-08 | Lilly Icos Llc, Wilmington | Kondensierte pyridoindolderivate |
| ATE337320T1 (de) | 2000-11-06 | 2006-09-15 | Lilly Icos Llc | Indolderivate als pde5-inhibitoren |
| CN1255185C (zh) | 2001-05-03 | 2006-05-10 | 弗·哈夫曼-拉罗切有限公司 | 无定形甲磺酸奈非那韦的药物剂型 |
| GB0202254D0 (en) | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| WO2003101276A2 (en) | 2002-05-22 | 2003-12-11 | Virginia Commonwealth University | Protective effects of pde-5 inhibitors |
| AU2003286555A1 (en) | 2002-10-22 | 2004-05-13 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases |
| GB0318094D0 (en) | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
| MX2007003731A (es) | 2004-09-29 | 2007-08-14 | Johnson & Johnson | Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables. |
| WO2007050585A2 (en) | 2005-10-24 | 2007-05-03 | The Johns Hopkins University | Use of a nitric oxide synthase modulator for the treatment of cardiac indications |
| US20080057590A1 (en) | 2006-06-07 | 2008-03-06 | Mickey Urdea | Markers associated with arteriovascular events and methods of use thereof |
| CA2720343A1 (en) * | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
| GB201114901D0 (en) | 2011-08-26 | 2011-10-12 | King S College London | Vascular treatments |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| ES2882258T3 (es) | 2012-12-21 | 2021-12-01 | Mayo Found Medical Education & Res | Métodos y materiales para tratar estenosis de la válvula aórtica calcificada |
| AU2014305843B2 (en) * | 2013-08-09 | 2019-08-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| MX2017014057A (es) * | 2015-05-06 | 2018-04-10 | Bayer Pharma AG | El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de ulceras digitales (du) concomitante con esclerosis sistemica (ssc). |
| US11202760B2 (en) * | 2016-09-30 | 2021-12-21 | Xenamed Corp. | Compositions of midodrine and methods of using the same |
| MX2019006938A (es) * | 2016-12-14 | 2019-09-06 | Respira Therapeutics Inc | Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. |
-
2020
- 2020-04-10 KR KR1020217036324A patent/KR20210150495A/ko active Pending
- 2020-04-10 WO PCT/US2020/027777 patent/WO2020210707A1/en not_active Ceased
- 2020-04-10 AU AU2020273183A patent/AU2020273183A1/en not_active Abandoned
- 2020-04-10 EP EP20788569.0A patent/EP3952992A4/en active Pending
- 2020-04-10 US US17/602,412 patent/US12465605B2/en active Active
- 2020-04-10 CN CN202080028080.5A patent/CN114144229A/zh active Pending
- 2020-04-10 SG SG11202110533RA patent/SG11202110533RA/en unknown
- 2020-04-10 MX MX2021012409A patent/MX2021012409A/es unknown
- 2020-04-10 CA CA3136550A patent/CA3136550A1/en active Pending
- 2020-04-10 JP JP2021559414A patent/JP2022526621A/ja not_active Withdrawn
-
2021
- 2021-10-07 IL IL287073A patent/IL287073A/en unknown
- 2021-10-08 MX MX2024010759A patent/MX2024010759A/es unknown
-
2025
- 2025-07-24 JP JP2025123759A patent/JP2025172729A/ja active Pending
- 2025-10-23 AU AU2025256169A patent/AU2025256169A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000491A1 (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas | |
| RU2020140891A (ru) | Производные пиразола в качестве ингибиторов калликреина | |
| JP2023506642A5 (https=) | ||
| EP3106163A1 (en) | Compositions and methods of treating pulmonary hypertension | |
| JP2013531028A5 (https=) | ||
| CA2534314C (en) | Benzothiazole derivatives for the treatment of diabetes | |
| RU2016129953A (ru) | Фармацевтические комбинации | |
| JP2005502643A5 (https=) | ||
| JP2007505083A5 (https=) | ||
| RU2017120858A (ru) | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина | |
| RU2012127760A (ru) | Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний | |
| RU2010129272A (ru) | Производные аминотриазола в качестве агонистов alх | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2016523976A5 (https=) | ||
| BR112012017713A2 (pt) | Aminopiridina, formulação farmacêutica, processo para a preparação de um derivado de aminopiridina, intermediário, e, uso de uma aminopiridina ou de uma formulação farmacêutica | |
| RU2008141509A (ru) | Mglur5 модуляторы 1 | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| JP2022526621A5 (https=) | ||
| JP2009532438A5 (https=) | ||
| JP6510549B2 (ja) | 運動失調性障害の予防または治療での使用におけるピリダジン誘導体 | |
| JP2011530607A5 (https=) | ||
| AU2013356294B2 (en) | Use of TRPV4 antagonists to ameliorate hydrocephalus and related materials and methods | |
| TW201010999A (en) | Treatment of pulmonary arterial hypertension | |
| RU2015128025A (ru) | Ингибиторы сомт | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 |